Last reviewed · How we verify

NCT06617104

Autonomic Nervous System and Meridian Energy in Patients With Schizophrenia

Recruiting now Last updated 2 October 2024
What this trial tests

trial testing no intervention in Schizophrenia in 100 participants. Currently enrolling.

Timeline
5 September 2024
Primary endpoint
19 August 2025
19 August 2025

Quick facts

Lead sponsorNational Taiwan University Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment100
Start date5 September 2024
Primary completion19 August 2025
Estimated completion19 August 2025
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

National Taiwan University Hospital

Who can join

Adults 18 to 65, any sex, with Schizophrenia or Healthy Individuals. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to explore the differences in autonomic nervous function and meridian energy between schizophrenia patients and healthy individuals. By understanding the meridian and organ conditions of individuals, the study aims to align with the traditional Chinese medicine (TCM) concept of "treating disease before it arises" and provide comprehensive care to patients, thereby improving the quality of care.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of no intervention

Trials testing the same drug.

Other recruiting trials for Schizophrenia

Currently open trials in the same condition.

Other National Taiwan University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06617104.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing